FDA Approves gammaCore Sapphire: Non-Invasive Vagus Nerve Stimulation for Migraine Prevention

Device Overview

On October 14, the FDA cleared the gammaCore Sapphire—a handheld, non-invasive vagus nerve stimulator (nVNS)—for preventive treatment of episodic migraine in adults.

Mechanism of Action

The device delivers mild electrical stimulation through the skin to the cervical vagus nerve in the neck. Vagus nerve activation modulates pain pathways in the brainstem and cortex, reducing migraine frequency and severity.

Indications

Approved for adults (≥18 years) with episodic migraine (0–14 headache days/month). Not indicated for chronic migraine (≥15 headache days/month).

Usage Protocol

Hold device against the neck over the vagus nerve for 2 minutes per session (typically 2 stimulations per session). Up to 3 sessions daily as needed. Patients may feel a tingling sensation; intensity is adjustable.

Side Effects

Most common: application-site pain, discomfort, or redness. Less common: hoarseness, throat irritation, cough, nausea, dizziness. No serious adverse events reported in trials.

Clinical Efficacy

In pivotal trials, gammaCore Sapphire reduced monthly migraine days by ~50% and migraine severity by ~30% on average compared to baseline.

Cost and Access

Device cost: $1,995 (may be covered by some insurance plans). Available by prescription only. Discuss with your headache specialist or neurologist to determine suitability.

Migraine - Related Articles